Latest Bicalutamide Stories
TOKYO and SAN FRANCISCO, March 24, 2015 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo: 4503) and Medivation, Inc.
NORTHBROOK, Ill. and SAN FRANCISCO, March 16, 2015 /PRNewswire/ -- Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503) and Medivation, Inc.
Hormonal therapies can help control advanced prostate cancer for a time.
While prostate cancer is the most common cancer in elderly Western men it also, but more rarely, strikes patients aged between 35 and 50.
Patients with castration-resistant prostate cancer treated with the androgen inhibitor abiraterone and who had high baseline hormone levels had longer overall survival compared with patients with low hormone levels.
Androgen suppression – the inhibition of testosterone and other male hormones – is a routine therapy for prostate cancer.
A new drug, MDV3100, is improving the survival rate in men with advanced prostate cancer, results of a large, phase III clinical trial show.
Homosexual men taking bicalutamide for prostate cancer were much more likely to report sexual problems during treatment than heterosexual patients.
SAN FRANCISCO and TOKYO, Nov. 29, 2010 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc.
SAN FRANCISCO and TOKYO, Sept. 29 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc.
- The governor of a province or people.